JP2016506933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506933A5 JP2016506933A5 JP2015555445A JP2015555445A JP2016506933A5 JP 2016506933 A5 JP2016506933 A5 JP 2016506933A5 JP 2015555445 A JP2015555445 A JP 2015555445A JP 2015555445 A JP2015555445 A JP 2015555445A JP 2016506933 A5 JP2016506933 A5 JP 2016506933A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- treatment
- use according
- naltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 claims description 49
- 230000001430 anti-depressive effect Effects 0.000 claims description 46
- 239000000935 antidepressant agent Substances 0.000 claims description 42
- 229940005513 antidepressants Drugs 0.000 claims description 42
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 36
- 229960003086 naltrexone Drugs 0.000 claims description 36
- 208000024714 major depressive disease Diseases 0.000 claims description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004372 aripiprazole Drugs 0.000 claims description 5
- 229960001058 bupropion Drugs 0.000 claims description 5
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical group CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 5
- 229960003089 pramipexole Drugs 0.000 claims description 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical group C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 5
- 229960002073 sertraline Drugs 0.000 claims description 5
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 7
- 229940005501 dopaminergic agent Drugs 0.000 claims 7
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical group C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 93
- 230000003291 dopaminomimetic effect Effects 0.000 description 24
- 230000002265 prevention Effects 0.000 description 20
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 19
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 19
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 19
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 19
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 11
- 102000015554 Dopamine receptor Human genes 0.000 description 8
- 108050004812 Dopamine receptor Proteins 0.000 description 8
- 229960001653 citalopram Drugs 0.000 description 8
- -1 s-citalopram Chemical compound 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 4
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 4
- 229960005217 dapoxetine Drugs 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 229960002866 duloxetine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 229960004038 fluvoxamine Drugs 0.000 description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 4
- 229960000600 milnacipran Drugs 0.000 description 4
- 229960001800 nefazodone Drugs 0.000 description 4
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 4
- 229960002296 paroxetine Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229960001879 ropinirole Drugs 0.000 description 4
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006203 subcutaneous dosage form Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758551P | 2013-01-30 | 2013-01-30 | |
| US61/758,551 | 2013-01-30 | ||
| US201361814476P | 2013-04-22 | 2013-04-22 | |
| US61/814,476 | 2013-04-22 | ||
| PCT/US2014/013874 WO2014120936A2 (en) | 2013-01-30 | 2014-01-30 | Treatments for depression and other diseases with a low dose agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506933A JP2016506933A (ja) | 2016-03-07 |
| JP2016506933A5 true JP2016506933A5 (enExample) | 2017-02-16 |
| JP6406713B2 JP6406713B2 (ja) | 2018-10-17 |
Family
ID=51263114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555445A Expired - Fee Related JP6406713B2 (ja) | 2013-01-30 | 2014-01-30 | 低用量薬剤によるうつ病および他の疾患の処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20150342946A1 (enExample) |
| EP (1) | EP2950799B1 (enExample) |
| JP (1) | JP6406713B2 (enExample) |
| CN (1) | CN104955483A (enExample) |
| CA (1) | CA2899455C (enExample) |
| HK (1) | HK1212254A1 (enExample) |
| WO (1) | WO2014120936A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2933733A1 (en) | 2013-12-20 | 2015-06-25 | Connie Sanchez Morillo | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
| CA2946698A1 (en) | 2014-04-22 | 2015-10-29 | Otsuka Pharmaceutical Co., Ltd. | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| US9616068B2 (en) * | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
| EP3416619A2 (en) * | 2016-02-18 | 2018-12-26 | Immune Therapeutics, Inc. | Method for inducing a sustained immune response |
| WO2018200381A1 (en) * | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CR20210368A (es) * | 2019-01-07 | 2021-12-10 | Antecip Bioventures Ii Llc | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
| US12465611B2 (en) | 2019-02-17 | 2025-11-11 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| EP3999058A4 (en) | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN |
| US12616702B2 (en) | 2019-12-03 | 2026-05-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CN121695144A (zh) * | 2020-11-27 | 2026-03-20 | 特雷泽制药私人有限公司 | 包含氟马西尼和纳曲酮的组合物及其使用方法 |
| GB202109022D0 (en) * | 2021-06-23 | 2021-08-04 | Ldn Pharma Ltd | Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 2a, 2b or 2c |
| EP4363057A4 (en) * | 2021-07-02 | 2025-04-16 | BioXcel Therapeutics, Inc. | METHODS OF TREATING DEPRESSIVE CONDITIONS |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| USRE36547E (en) | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DK0782445T3 (da) | 1994-09-19 | 2002-05-06 | Bristol Myers Squibb Pharma Co | Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| US6001848A (en) | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
| US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| CA2290788A1 (en) | 1997-05-20 | 1998-11-26 | Suchitra Krishnan-Sarin | Substance dependence treatment using opiate antagonists and serotonin compounds |
| GB9815618D0 (en) | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
| US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| EP1326642A2 (en) | 2000-09-29 | 2003-07-16 | Board of Trustees operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
| AR031152A1 (es) | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US20030087896A1 (en) * | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| EP1870096A3 (en) | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| AU2005244852B2 (en) | 2004-05-12 | 2011-09-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods related to the treatment of neurodegenerative and inflammatory conditions |
| US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20080045610A1 (en) | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| JP2009517393A (ja) | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| WO2007100775A2 (en) | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20070232638A1 (en) | 2006-04-03 | 2007-10-04 | Howard Brooks-Korn | Opiopathies |
| EA200870449A1 (ru) | 2006-04-19 | 2009-04-28 | Джилл П. Смит | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами |
| US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| CA2702694A1 (en) | 2006-11-01 | 2008-05-22 | Albert Einstein College Of Medicine Of Yeshiva University | Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator |
| JP2010537990A (ja) * | 2007-08-27 | 2010-12-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ |
| US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
| WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
| US9789093B2 (en) | 2011-01-31 | 2017-10-17 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
-
2014
- 2014-01-30 CA CA2899455A patent/CA2899455C/en active Active
- 2014-01-30 JP JP2015555445A patent/JP6406713B2/ja not_active Expired - Fee Related
- 2014-01-30 US US14/410,551 patent/US20150342946A1/en not_active Abandoned
- 2014-01-30 HK HK16100404.2A patent/HK1212254A1/xx unknown
- 2014-01-30 CN CN201480006714.1A patent/CN104955483A/zh active Pending
- 2014-01-30 EP EP14746250.1A patent/EP2950799B1/en active Active
- 2014-01-30 WO PCT/US2014/013874 patent/WO2014120936A2/en not_active Ceased
-
2015
- 2015-03-05 US US14/639,797 patent/US9278094B2/en active Active
-
2016
- 2016-01-28 US US15/009,415 patent/US20160310484A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/031,662 patent/US20180318289A1/en not_active Abandoned
-
2019
- 2019-04-09 US US16/379,042 patent/US20190231772A1/en not_active Abandoned
- 2019-07-23 US US16/519,638 patent/US20190343829A1/en not_active Abandoned
-
2020
- 2020-03-05 US US16/810,188 patent/US20200197388A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| JP6406713B2 (ja) | 低用量薬剤によるうつ病および他の疾患の処置 | |
| JP2016540738A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| JP2016536286A5 (enExample) | ||
| AR079862A1 (es) | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion | |
| JP2015534562A5 (enExample) | ||
| HRP20240817T1 (hr) | Kombinirana terapija koja sadrži ivosidenib, citarabin i daunorubicin ili idarubicin za liječenje akutne mijelogene leukemije | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| JP2015505564A5 (enExample) | ||
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| HRP20211790T1 (hr) | Kombinirana terapija za liječenje maligniteta | |
| JP5650134B2 (ja) | ５‐ベンジルアミノサリチル酸誘導体またはその塩の医薬用途 | |
| HRP20230168T1 (hr) | Inhibicija mutanta idh-1 | |
| CL2023003259A1 (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| JP2017511377A5 (enExample) | ||
| JP2016525548A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2015522077A5 (enExample) | ||
| JP2010530867A (ja) | うつ病の治療 | |
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| JP2022517902A5 (enExample) |